The journey from research to medicine is highly vulnerable to funding and manpower interruption. Only large pharmaceutical companies can vertically integrate and go bench-to-patient but the DMD patient population is too small for commercial medicine development. That means research that demonstrably reduces DMD muscle cell damage simply stops without a "sponsor" who will take it to trials and then medicine.

The RaceMD objective is to compress time and eliminate barriers, when that is humanly possible.

Our goal is to speed up the therapies that keep DMD boys as healthy as possible until a cure for Duchenne Muscular Dystrophy is found.  These disease-modifying therapies (DMTs) can aid in the preservation of the muscle cells of DMD boys.  Because injury is ongoing in the muscle cells of all DMD boys, our mission is a race.

>  Clinical Trial, Massachusetts General Hospital, Deflazacourt and Arginine

>  Muscle stem cell regeneration compound, University of Washington

>  Commercial Development, muscle regeneration, DMD boys

>  Duchenne Alliance, United to Beat Time, scientific collaborations